Full history for every metric is available with a Kvantra account
InDex Pharmaceuticals Holding AB (publ) (INDEX.ST)
Key financial summary
Financials in SEK| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | SEK m | 0 | 0 | 0 | 0 | 1 | 98 | 108 |
| Operating profit | SEK m | -96 | -56 | |||||
| Net profit | SEK m | -82 | -88 | -58 | -103 | -97 | -95 | -56 |
| EPS reported | SEK | -0.18 | -0.11 | |||||
| Operating cashflow per share | SEK | -0.07 | -0.07 | |||||
| Capex per share | SEK | 0.00 | 0.00 | |||||
| FCF per share | SEK | -0.07 | -0.07 | |||||
| Free cash flow | SEK m | -38 | -49 | |||||
| Net debt | SEK m | -292 | -269 | |||||
| Book value equity | SEK m | 239 | 236 | |||||
| Book value per share | SEK | 0.45 | 0.44 | |||||
| Number of shares | m | 532.69 | 532.69 | |||||
| DPS (TTM paid) | SEK | 0.00 | 0.00 |
Financial summary
Financials in SEK| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.57 | 15.62 | |||||
| P/S LTM | x | 1.40 | 34.03 | |||||
| P/FCF LTM | x | -3.59 | -75.99 | |||||
| EV/EBITDA LTM | x | 1.66 | -61.94 | |||||
| EV/Sales LTM | x | -1.60 | 31.54 | |||||
| Earnings Yield LTM | % | -69.86% | -32.05% | |||||
| FCF Yield | % | -27.85% | -1.32% | |||||
| Quality | ||||||||
| ROE | % | -39.88% | -33.26% | |||||
| ROIC | % | -39.68% | -39.68% | |||||
| Operating margin | % | -98.16% | -98.16% | |||||
| Gross margin | % | -98.16% | -98.16% | |||||
| FCF/Sales | % | -38.95% | -38.95% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +8408.3% | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -16.53 | -23.69 | |||||
| Net Debt/EBITDA | x | 3.11 | 3.11 | |||||
| EBIT/Net interest | x | -421.62 | -421.62 | |||||
| Net debt/market cap | % | -214.10% | -7.30% | |||||
| Net debt/Equity | x | -1.22 | -1.14 | |||||
| Gross debt/equity | x | 0.01 | 0.01 | |||||
Company overview
InDex Pharmaceuticals Holding AB (publ) is a pharmaceutical firm dedicated to developing therapeutic solutions for patients affected by ulcerative colitis. The company's flagship drug candidate, Cobitolimod, is presently in Phase III clinical trials, targeting the treatment of moderate to severe ulcerative colitis. Furthermore, InDex is progressing a pipeline of other DNA-based immunomodulatory sequences, which are in the preclinical phase, designed to address various immunological conditions. This enterprise was established in 2000 and operates from its headquarters in Solna, Sweden.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
InDex Pharmaceuticals Holding AB (publ) (INDEX.ST)
InDex Pharmaceuticals Holding AB (publ) is a pharmaceutical firm dedicated to developing therapeutic solutions for patients affected by ulcerative colitis. The company's flagship drug candidate, Cobitolimod, is presently in Phase III clinical trials, targeting the treatment of moderate to severe ulcerative colitis. Furthermore, InDex is progressing a pipeline of other DNA-based immunomodulatory sequences, which are in the preclinical phase, designed to address various immunological conditions. This enterprise was established in 2000 and operates from its headquarters in Solna, Sweden.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free